Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
IMC-F106C Combinations for Solid Cancers
Recruiting1 awardPhase 1 & 2
Montréal, Quebec
This trial is designed to see if a new T cell receptor, IMC-F106C, is safe and effective in treating patients with cancer that is positive for the tumor-associated antigen PRAME.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.